🔗 Share this article

While the US proceeds with historic adjustments to its vaccine recommendations, one figure appears unexpectedly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by casting doubt on Covid shots during the pandemic and has focused upon potential deaths after COVID-19 vaccination in her recent time at the FDA.

Planned Shifts to Childhood Immunization Program

Public health authorities had intended to announce major revisions to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s national calendar, sources say – a substantial departure that would place the US at odds with a large portion of the global community with insufficient data for improved outcomes. This reveal has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to head the division this year.

Consolidating Power at the Agency

This interim role might represent a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has often pushed for ending specific childhood immunization guidelines in the US so as to align more in line with Denmark's approach, a society with universal health coverage and a population approximately the population of Wisconsin’s.

In her initial comments, she has kept her attention on vaccination policy – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – rather than pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has no obvious track record in drug development, approval processes or administrative roles, which has been customary for previous heads of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and CBER since March.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She lacks experience in leading a major agency. She is not an expert in drug approvals.”

Past heads of CBER would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, said Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who headed the center have had.”

CDER has an immense workload at the agency, she stated.

“The public just pays attention on the novel medication approvals, but the generic program clears numerous generic drugs. There is also a biosimilars program, over-the-counter program and so forth, and each of these have to be managed,” Dr. Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a substantial administrative element to the job, which oversees in excess of 5,000 employees. “It’s a huge management job, if you perform it correctly,” Woodcock concluded.

Response and Disputed Policies

Regarding concerns about Dr. Høeg's credentials and whether this assignment signifies greater collaboration among FDA leaders on vaccines, a spokesperson said that the “concerns stem from flawed presumptions”.

“Her resume aligns with the functions of her role,” the official said, pointing to the period Dr. Høeg spent guiding the agency head on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious rapid therapy clearance system that reportedly troubled her preceding directors. “How are these drugs being picked for this fast-track system? Who is making the choices?” Dr. Howard said. “There is a lot of confidentiality going on at the FDA right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards less stringent regulations of most medications, with the exception of shots.”

Public Past Work on Immunizations

Concerning immunizations, Høeg has a more established, if troubling, track record, Howard observe. She released a research paper using unverified public submissions to determine the frequency of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are riskier than they are.

Among her “policy goals” for the current administration featured altering rules for new vaccines and discontinuing “non-essential” immunizations, she stated following the vote on a audio program. At the FDA, Høeg has reportedly proposed barring young men from receiving COVID-19 vaccines.

“She is an thorough ideologue who commences with her conclusions and tailors the evidence to accommodate the evidence in a extremely misleading, fraudulent fashion,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with other dissenters, {like|